Clinical Trials (PDQ®) - National Cancer Institute

Page Options

Clinical Trial Questions?

Get Help:

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase II Treatment Completed 18 and over Pharmaceutical / Industry A4061023
NCT00282048

Trial Description

Summary

To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).

Eligibility Criteria

Inclusion Criteria:

RCC with metastases and nephrectomy

failure of prior sorafenib-based therapy

at least 1 target lesion that has not been irradiated

adequate bone marrow, hepatic and renal function, > or equal to 18 years of age.

Exclusion Criteria:

Gastrointestinal abnormalities

current use or inability to avoid chronic antacid therapy

current use or anticipated inability to avoid potent CYP3A4 inhibitors or CYP1A2 inducers

active seizure disorder or evidence of brain metastases.

Trial Contact Information

Trial Lead Organizations/Sponsors

Pfizer Incorporated

Pfizer CT.gov Call Center

Study Director

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00282048
Information obtained from ClinicalTrials.gov on November 16, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.